Tweet
Celtic licenses Resolvyx Pharma dry eye syndrome compound
Celtic Therapeutics has licensed and taken over worldwide rights related to Resolvyx Pharmaceuticals' RX-10045 as a treatment of dry eye syndrome and other ophthalmic conditions.
Resolvyx Pharma has scheduled RX-10045 Phase III randomized, placebo-controlled, multi-center study in 2011.
Under the agreement, Celtic Therapeutics may also license rights to and develop a second Resolvyx compound in a topical formulation for ophthalmic indications.
Resolvyx Pharma has scheduled RX-10045 Phase III randomized, placebo-controlled, multi-center study in 2011.
Under the agreement, Celtic Therapeutics may also license rights to and develop a second Resolvyx compound in a topical formulation for ophthalmic indications.